Santarus reps pushing Naprelan

Share this article:
Santarus said its sales reps will commence promotional activities in the third quarter for Victory Pharma's Naprelan brand products under a recent co-promotion agreement.

Naprelan tablets are a once daily control-release formulation of the non-steroidal anti-
inflammatory drug (NSAID) naproxen sodium, indicated for pain relief caused by a number of conditions including arthritis.

Santarus said it plans to promote Naprelan to targeted primary care physicians. Reps will also continue to promote the company's Rx heartburn treatment Zegerid to gastroenterologists and primary care doctors alongside reps from inVentiv and Otsuka America.  

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.